Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK3389245A (ChAd155-RSV) in Healthy Adults
NCT02491463Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAd155-RSV in respiratory syncytial virus infection (RSV) (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Solicited Local Symptoms, Number of Subjects With Solicited General Symptoms and 3 more. Started Jul 2015; status: completed.
02
Drugs
ChAd155-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02491463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491463.